<DOC>
	<DOCNO>NCT00650143</DOCNO>
	<brief_summary>Trial design : This Phase III , investigator-driven , randomised , placebo-controlled efficacy safety study compare effect Sitagliptin combination granulocyte-colony stimulate factor ( Lenograstim , G-CSF ) improvement myocardial function patient undergoing routine percutaneous coronary revascularisation acute myocardial infarction ( time onset infarction intervention 2 24 hour ) . The primary objective study compare treatment G-CSF plus Sitagliptin , ( G-CSF/Sitagliptin treatment group , n=87 ) versus Placebo ( control treatment group , n=87 ) change global myocardial function baseline 6 month follow-up .</brief_summary>
	<brief_title>Sitagliptin Plus Granulocyte-colony Stimulating Factor Acute Myocardial Infarction</brief_title>
	<detailed_description>The trial conduct multi-centre trial . Secondary objective study monitor change regional myocardial function , myocardial perfusion extent non-viable myocardium baseline 6 month revascularisation treatment group . Furthermore follow parameter 12 month follow-up analysed : occurrence major adverse cardiac event ( death , myocardial infarction , coronary bypass grafting , re-intervention ) , spontaneously report adverse event . Analyses cardiac function consist evaluation segmental systolic wall thickening , end-diastolic volume , end-systolic volume , stroke volume , ejection fraction cardiac output mean magnetic resonance imaging ( MRI ) . The extent non-viable myocardium myocardial perfusion assess use contrast enhance MRI . This study consist revascularisation period ( angioplasty infarcted vessel ) , treatment period ( 28 day ) , follow-up period ( 12 month ) . The Revascularisation Period start treatment patient emergency room . As soon possible patient transfer catheterisation laboratory acute percutaneous coronary intervention ( PCI ) infarct-related artery perform . The first phase Treatment Period consist screen period patient 's eligibility preliminarily evaluate . The second phase Treatment Period randomisation patient control G-CSF/Sitagliptin treatment group . After baseline MRI , patient randomise . Patients treat either G-CSF ( 10Âµg/kg/d divide two dos subcutaneously ) period 5 day Sitagliptin 100 mg day 28 day placebo . Patients randomise 1:1 ratio control verum therapy treatment group . Follow-up Period assessment perform patient 6 month include clinical status , occurrence adverse event , laboratory investigation , MRI . To assess occurrence in-stent restenosis , routine control angiography perform patient 6 month initial PCI . Safety evaluate monitor treatment-emergent sign symptom , 12-lead ECGs , vital sign , physical examination , clinical laboratory assessment 1 month 1 year .</detailed_description>
	<mesh_term>Infarction</mesh_term>
	<mesh_term>Myocardial Infarction</mesh_term>
	<mesh_term>Lenograstim</mesh_term>
	<mesh_term>Sitagliptin Phosphate</mesh_term>
	<criteria>Inclusion criterion 1 . Be least 18 year old , male female 2 . Have acute ST segment elevation myocardial infarction ( typical chest pain 30 minute duration , presence STsegment elevation least two contiguous lead leave bundlebranch block ) and/or occlude coronary artery 3 . Intervention infarct related artery PCI/Stenting within 224 hour onset acute myocardial infarction . 4. creatinin kinase elevation three time upper normal level ( i.e . 540 U/l ) accompany significant elevation CKMB isoenzyme and/or Troponin I/T 5 . Have regional wall motion abnormality ( comprise hypo , dyskinesia ) least one myocardial segment demonstrate MRI . 6 . Patients suitable coronary angiography angioplasty stenting infarct relate artery . 7 . Have ability understand requirement study , agree able return require assessment . 8 . Give write informed consent . Exclusion criterion General : 1 . Women childbearing potential , pregnancy lactating . 2 . Be unable undergo percutaneous cardiac catheterisation 3 . Have contraindication magnetic resonance imaging ( e.g . nonMR compatible implant medical device ) 4 . Have condition may severely degrade image quality ( e.g . severe arrhythmia ) prevent MR scanning ( e.g . claustrophobia ) 5 . Previous enrolment present trial administration study medication within previous 30 day . Study drug define material ( placebo drug ) dispense provision protocol . 6 . Have severe concurrent illness ( e.g. , active infection , malignancy ) . 7 . Life expectancy less one year . 8 . Have history alcohol drug abuse within 3 month prior admission factor jeopardise followup . Renal , hepatic , metabolic : 1 . Moderate severe renal impairment ( Crea level &gt; 1.7 mg/dL glomerular filtration rate &lt; 35 ml/min ) . 2 . Diabetes type 1 patient . 3 . Diabetic ketoacidosis . 4 . Concomitant medication know cause hypoglycemia , sulfonylureas . 5 . Severe liver dysfunction . Haematologic : 1 . Malignant haematological disease , i.e . chronic myeloic leukemia ( CML ) myelodysplastic syndrome ( MDS ) 2 . Severe congenital neutropenia cytogenetic abnormality 3 . Known allergic reaction vs. Lenograstim Cardiovascular : 1 . Acute cardiogenic shock 2 . Cardiomyopathy ejection fraction 0.25 ( i.e . ischemic dilate cardiomyopathy result congestive heart failure ) 3 . Infective endocarditis 4 . Factors contraindicate cardiac catheterisation ( e.g . severe allergy iodine , severe thyroid disease ) 5 . Planned operative revascularisation 6 . Left ventricular thrombus 7 . Severe cardiac arrhythmia ( i.e . malignant sustain nonsustained ventricular tachycardia ventricular fibrillation ) within 24 hour admission . Pulmonary : 1 . Acute massive pulmonary infiltration 2 . History pneumonia last 4 week Other : 1 . Therapy immunosuppressant , cytostatics , corticoid .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2011</verification_date>
	<keyword>Stem cell</keyword>
	<keyword>Myocardial infarction</keyword>
	<keyword>G-CSF</keyword>
	<keyword>CD26-inhibition</keyword>
</DOC>